[Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis]
- PMID: 27545124
- DOI: 10.3760/cma.j.issn.0253-3758.2016.08.006
[Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis]
Abstract
Objective: To analyze the current status of cholesterol goal attainment for the primary and secondary prevention of cardiovascular disease in dyslipidemia patients using data from the DYSIS-China study.
Methods: Based on criteria defined in the 2014 China Cholesterol Education Program (CCEP) and the 2007 Chinese guidelines for the prevention and treatment of dyslipidemia in adults, 25 317 dyslipidemia patients enrolled in the DYSIS-China study (from March 2012 to October 2012) were stratified to the atherosclerotic cardiovascular disease(ASCVD) primary prevention and secondary prevention groups. The total cholesterol (TC) target goals were <3.11, 4.14, 5.18, and 6.22 mmol/L, respectively, and the low-density lipoprotein cholesterol (LDL-C) therapeutic goals were less than 1.8, 2.6, 3.4, and 4.1 mmol/L, respectively, for the very high-risk, high-risk, moderate-risk, and low-risk patients in the primary prevention group. The TC targets for the very high-risk and high-risk patients were <3.11 and <4.14 mmol/L, respectively, and the LDL-C targets were <1.8 and <2.6 mmol/L, respectively, in the secondary prevention group. The TC and LDL-C goal attainment rates were calculated for the different risk groups according to the targets values.
Results: Totally, 71.09% (n=18 000) of the dyslipidemia patients were grouped into very high and high risk groups, 51.76% (n=13 104) and 48.24% (n=12 213) patients were stratified to primary and secondary prevention of ASCVD. The LDL-C and TC goal attainment rates for the secondary prevention group were 33.09%(4 041 cases) and 21.05% (2 571 cases), respectively. The LDL-C and TC goal attainment rates for the primary prevention group were 52.40% (6 866 cases) and 42.06% (5 511 cases), respectively. Multivariate logistic regression analysis showed that diabetes mellitus(OR=5.75, 4.15, P<0.05), coronary heart disease(OR=5.70, 3.58, P<0.001), and peripheral arterial disease(OR=2.42, 1.49, P<0.05) were risk factors for failure to achieve TC and LDL-C goals, respectively.
Conclusions: Despite the widespread application of the 2014 CCEP and 2007 Chinese dyslipidemia guidelines, LDL-C goal attainment among secondary and primary prevention patients remains suboptimal in China. More rigorous guideline adherence is therefore required to increase the LDL-C and TC goal attainment rates and improve the long-term cardiovascular outcomes in Chinese dyslipidemia patients.
Similar articles
-
Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).Atherosclerosis. 2014 Nov;237(1):99-105. doi: 10.1016/j.atherosclerosis.2014.08.023. Epub 2014 Sep 1. Atherosclerosis. 2014. PMID: 25238215
-
Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.Atherosclerosis. 2018 Jan;268:99-107. doi: 10.1016/j.atherosclerosis.2017.11.020. Epub 2017 Nov 20. Atherosclerosis. 2018. PMID: 29197254
-
Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy.Lipids Health Dis. 2019 Jan 29;18(1):32. doi: 10.1186/s12944-019-0974-y. Lipids Health Dis. 2019. PMID: 30696435 Free PMC article.
-
Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?Expert Rev Cardiovasc Ther. 2024 Sep;22(9):441-457. doi: 10.1080/14779072.2024.2398444. Epub 2024 Sep 1. Expert Rev Cardiovasc Ther. 2024. PMID: 39198976 Review.
-
Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.Curr Cardiol Rep. 2019 Aug 5;21(9):110. doi: 10.1007/s11886-019-1175-z. Curr Cardiol Rep. 2019. PMID: 31378838 Review.
Cited by
-
Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II.Clin Cardiol. 2021 Nov;44(11):1575-1585. doi: 10.1002/clc.23725. Epub 2021 Oct 15. Clin Cardiol. 2021. PMID: 34651329 Free PMC article.
-
Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study).J Geriatr Cardiol. 2021 Apr 28;18(4):261-270. doi: 10.11909/j.issn.1671-5411.2021.04.005. J Geriatr Cardiol. 2021. PMID: 33995505 Free PMC article.
-
Relationship between childhood secondhand smoke exposure and the occurrence of hyperlipidaemia and coronary heart disease among Chinese non-smoking women: a cross-sectional study.BMJ Open. 2021 Jul 5;11(7):e048590. doi: 10.1136/bmjopen-2020-048590. BMJ Open. 2021. PMID: 34226229 Free PMC article.
-
Regional Dietary Pattern Associated with the Risk of Hypertensive Dyslipidemia Multimorbidity in Chinese Elderly: Results from China Nutrition and Health Surveillance in 2015-2017.Nutrients. 2025 Feb 28;17(5):852. doi: 10.3390/nu17050852. Nutrients. 2025. PMID: 40077723 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical